ARID1B and non-small cell lung carcinoma: The prognosis analysis of 350 NSCLC patients who underwent ICIs therapy, we also discovered that patients with ARID1B mutation exhibited better outcomes following ICIs treatment, the median progress free survival time is 22.43 months for altered group compared to 3.77 months for non-altered group (Fig. 1G).